Monitor for study initiation in Q1 2027 and any interim data readouts. The collaboration validates pelareorep's potential in HPV-associated cancers but provides no near-term revenue. Success could open a broader development path across HPV-positive tumors.
Drugs in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $0.3720entry
- T+1 · 4d ago −0.54%α −0.17% · $0.3700
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate its investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi) in a clinical study for patients with squamous cell anal carcinoma (SCAC) who have progressed on first-line therapy. The study is expected to begin in Q1 2027 at a U.S. cancer center, with Coherus supplying LOQTORZI. This is a non-financial collaboration that provides drug supply and supports a focused clinical evaluation in an indication with no approved second-line therapy.
Key Facts
- Oncolytics entered a clinical supply agreement with Coherus Oncology for a study combining pelareorep and toripalimab in second-line SCAC patients.
- The study is expected to begin in Q1 2027 at a premier U.S. cancer center.
- No approved therapy exists for second-line SCAC patients.
- Coherus will provide LOQTORZI (toripalimab-tpzi) to Oncolytics; no financial terms were disclosed.
- Pelareorep has Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer.
Financial Impact
No financial terms disclosed; drug supply agreement only.
Risk Factors
- Clinical trial may fail to show efficacy in second-line SCAC patients.
- No financial consideration disclosed; value depends entirely on clinical outcomes.
- Study enrollment and timeline may be delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401132 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Viewing Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers